Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells.

PubWeight™: 1.69‹?› | Rank: Top 3%

🔗 View Article (PMID 11046049)

Published in J Immunol on November 01, 2000

Authors

C Devito1, K Broliden, R Kaul, L Svensson, K Johansen, P Kiama, J Kimani, L Lopalco, S Piconi, J J Bwayo, F Plummer, M Clerici, J Hinkula

Author Affiliations

1: Department of Clinical Virology, Karolinska Institute, Huddinge University Hospital, Stockholm, Sweden.

Articles citing this

HIV infection and the gastrointestinal immune system. Mucosal Immunol (2008) 3.14

CD8(+) lymphocytes respond to different HIV epitopes in seronegative and infected subjects. J Clin Invest (2001) 2.15

Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol (2010) 1.91

Cervicovaginal HIV-1-neutralizing immunoglobulin A detected among HIV-1-exposed seronegative female partners in HIV-1-discordant couples. AIDS (2012) 1.64

Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J Virol (2003) 1.41

Critical issues in mucosal immunity for HIV-1 vaccine development. J Allergy Clin Immunol (2008) 1.41

Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations. J Gen Virol (2011) 1.27

HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life. Mucosal Immunol (2013) 1.23

Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization. J Virol (2002) 1.20

Multi-faceted functions of secretory IgA at mucosal surfaces. Front Immunol (2013) 1.19

GP41-specific antibody blocks cell-free HIV type 1 transcytosis through human rectal mucosa and model colonic epithelium. J Immunol (2010) 1.15

Evidence for the innate immune response as a correlate of protection in human immunodeficiency virus (HIV)-1 highly exposed seronegative subjects (HESN). Clin Exp Immunol (2011) 1.11

Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines. Clin Vaccine Immunol (2014) 1.06

A mucosally targeted subunit vaccine candidate eliciting HIV-1 transcytosis-blocking Abs. Proc Natl Acad Sci U S A (2004) 1.04

HIV is inactivated after transepithelial migration via adult oral epithelial cells but not fetal epithelial cells. Virology (2010) 0.99

Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques. Nat Med (2016) 0.98

A systems biology examination of the human female genital tract shows compartmentalization of immune factor expression. J Virol (2013) 0.97

Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes. PLoS One (2013) 0.96

Mucosal immunity in human and simian immunodeficiency lentivirus infections. Mucosal Immunol (2013) 0.96

Immune responses to HIV and SIV in mucosal tissues: 'location, location, location'. Curr Opin HIV AIDS (2010) 0.96

HIV acquisition is associated with increased antimicrobial peptides and reduced HIV neutralizing IgA in the foreskin prepuce of uncircumcised men. PLoS Pathog (2014) 0.92

HIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in Southern Africa are primarily directed toward gp120 and gp140 specificities. PLoS One (2014) 0.91

Oral immunization with recombinant listeria monocytogenes controls virus load after vaginal challenge with feline immunodeficiency virus. J Virol (2004) 0.91

Mucosal and systemic immune responses to a human immunodeficiency virus type 1 epitope induced upon vaginal infection with a recombinant influenza A virus. J Virol (2004) 0.90

Mucosal immunity to HIV: a review of recent literature. Curr Opin HIV AIDS (2008) 0.89

CCL28 induces mucosal homing of HIV-1-specific IgA-secreting plasma cells in mice immunized with HIV-1 virus-like particles. PLoS One (2011) 0.89

Rapid SIV Env-specific mucosal and serum antibody induction augments cellular immunity in protecting immunized, elite-controller macaques against high dose heterologous SIV challenge. Virology (2011) 0.89

Induction of mucosal and systemic antibody responses against the HIV coreceptor CCR5 upon intramuscular immunization and aerosol delivery of a virus-like particle based vaccine. Vaccine (2009) 0.87

Default in plasma and intestinal IgA responses during acute infection by simian immunodeficiency virus. Retrovirology (2012) 0.87

Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection. J Virol (2012) 0.86

Transcytosis-blocking abs elicited by an oligomeric immunogen based on the membrane proximal region of HIV-1 gp41 target non-neutralizing epitopes. Curr HIV Res (2008) 0.85

Excretion of human immunodeficiency virus type 1 through polarized epithelium by immunoglobulin A. J Virol (2008) 0.85

Exosomes in human semen restrict HIV-1 transmission by vaginal cells and block intravaginal replication of LP-BM5 murine AIDS virus complex. Virology (2015) 0.85

Intranasal vaccination using interleukin-12 and cholera toxin subunit B as adjuvants to enhance mucosal and systemic immunity to human immunodeficiency virus type 1 glycoproteins. J Virol (2003) 0.84

A comparative proteomic analysis of the soluble immune factor environment of rectal and oral mucosa. PLoS One (2014) 0.84

The mucosae-associated epithelial chemokine (MEC/CCL28) modulates immunity in HIV infection. PLoS One (2007) 0.84

Heterosexual and homosexual partners practising unprotected sex may develop allogeneic immunity and to a lesser extent tolerance. PLoS One (2009) 0.84

Microbial Translocation and B Cell Dysfunction in Human Immunodeficiency Virus Disease. Am J Immunol (2012) 0.83

Pseudo-mannosylated DC-SIGN ligands as potential adjuvants for HIV vaccines. Viruses (2014) 0.83

Intranasal administration of a therapeutic HIV vaccine (Vacc-4x) induces dose-dependent systemic and mucosal immune responses in a randomized controlled trial. PLoS One (2014) 0.83

Are anti-HIV IgAs good guys or bad guys? Retrovirology (2014) 0.83

Transcytosis of HIV-1 through vaginal epithelial cells is dependent on trafficking to the endocytic recycling pathway. PLoS One (2014) 0.83

Quantitative analysis of differentially expressed saliva proteins in human immunodeficiency virus type 1 (HIV-1) infected individuals. Anal Chim Acta (2013) 0.83

Evaluation of heterologous vaginal SHIV SF162p4 infection following vaccination with a polyvalent Clade B virus-like particle vaccine. AIDS Res Hum Retroviruses (2012) 0.82

Impact of IgA constant domain on HIV-1 neutralizing function of monoclonal antibody F425A1g8. J Immunol (2012) 0.81

Immunoglobulin A: A next generation of therapeutic antibodies? MAbs (2011) 0.81

Induction of Potent and Long-Lived Antibody and Cellular Immune Responses in the Genitorectal Mucosa Could be the Critical Determinant of HIV Vaccine Efficacy. Front Immunol (2014) 0.81

Use of broadly neutralizing antibodies for HIV-1 prevention. Immunol Rev (2017) 0.80

Lactobacillus rhamnosus GG Suppresses Meningitic E. coli K1 Penetration across Human Intestinal Epithelial Cells In Vitro and Protects Neonatal Rats against Experimental Hematogenous Meningitis. Int J Microbiol (2008) 0.79

Natural anti-CCR5 antibodies in HIV-infection and -exposure. J Transl Med (2011) 0.79

How can we design better vaccines to prevent HIV infection in women? Front Microbiol (2014) 0.79

Bovine papillomavirus-like particles presenting conserved epitopes from membrane-proximal external region of HIV-1 gp41 induced mucosal and systemic antibodies. Vaccine (2013) 0.79

Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel. Mucosal Immunol (2016) 0.78

Mucosal correlates of protection in HIV-1-exposed sero-negative persons. Am J Reprod Immunol (2014) 0.78

IgM Repertoire Biodiversity is Reduced in HIV-1 Infection and Systemic Lupus Erythematosus. Front Immunol (2013) 0.78

Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection. Vaccines (Basel) (2016) 0.77

Recombinant expression, purification, and biophysical characterization of the transmembrane and membrane proximal domains of HIV-1 gp41. Protein Sci (2014) 0.77

A HIV-Tat/C4-binding protein chimera encoded by a DNA vaccine is highly immunogenic and contains acute EcoHIV infection in mice. Sci Rep (2016) 0.76

Challenges in mucosal HIV vaccine development: lessons from non-human primate models. Viruses (2014) 0.76

Biophysical Characterization of a Vaccine Candidate against HIV-1: The Transmembrane and Membrane Proximal Domains of HIV-1 gp41 as a Maltose Binding Protein Fusion. PLoS One (2015) 0.76

HIV-1-Neutralizing IgA Detected in Genital Secretions of Highly HIV-1-Exposed Seronegative Women on Oral Preexposure Prophylaxis. J Virol (2016) 0.75

A Little Help From the Follicles: Understanding the Germinal Center Response to Human Immunodeficiency Virus 1 Infection and Prophylactic Vaccines. Clin Med Insights Pathol (2017) 0.75

Immunological Characterization of Plant-Based HIV-1 Gag/Dgp41 Virus-Like Particles. PLoS One (2016) 0.75

Sublingual Priming with a HIV gp41-Based Subunit Vaccine Elicits Mucosal Antibodies and Persistent B Memory Responses in Non-Human Primates. Front Immunol (2017) 0.75

Mother-to-Child HIV-1 Transmission Events Are Differentially Impacted by Breast Milk and Its Components from HIV-1-Infected Women. PLoS One (2015) 0.75

Mucosal vaccination with a live recombinant rhinovirus followed by intradermal DNA administration elicits potent and protective HIV-specific immune responses. Sci Rep (2016) 0.75

New prospects for a preventive HIV-1 vaccine. J Virus Erad (2015) 0.75

Articles by these authors

Initial sequencing and analysis of the human genome. Nature (2001) 212.86

Chilamydia trachomatis infection in patients with acute salpingitis. N Engl J Med (1977) 9.68

The genome of the natural genetic engineer Agrobacterium tumefaciens C58. Science (2001) 6.90

Effect of circumcision on incidence of human immunodeficiency virus type 1 and other sexually transmitted diseases: a prospective cohort study of trucking company employees in Kenya. J Infect Dis (1999) 5.86

T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science (1995) 3.87

Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol (2002) 3.75

Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet (1996) 3.65

Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J Clin Invest (1998) 3.53

Importance of enteric adenoviruses 40 and 41 in acute gastroenteritis in infants and young children. J Clin Microbiol (1984) 3.32

Antibodies to Chlamydia trachomatis in acute salpingitis. Br J Vener Dis (1979) 3.32

Role of T-cell derived cytokines in the downregulation of immune responses in parasitic and retroviral infection. Immunol Rev (1992) 3.30

HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat Med (1997) 3.22

Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina. Lancet (1997) 2.88

The checkpoint protein Ddc2, functionally related to S. pombe Rad26, interacts with Mec1 and is regulated by Mec1-dependent phosphorylation in budding yeast. Genes Dev (2000) 2.82

Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev (1996) 2.77

Enteropathogens in adult patients with diarrhea and healthy control subjects: a 1-year prospective study in a Swedish clinic for infectious diseases. Clin Infect Dis (2000) 2.77

HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. J Immunol (2000) 2.69

Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med (1999) 2.54

Incipient nephropathy in type 1 (insulin-dependent) diabetes. Diabetologia (1984) 2.50

Complete genome sequence of the genetically tractable hydrogenotrophic methanogen Methanococcus maripaludis. J Bacteriol (2004) 2.47

The DNA sequence and biological annotation of human chromosome 1. Nature (2006) 2.42

Frequency of human parvovirus B19 infection in intrauterine fetal death. Lancet (2001) 2.42

Isolation of human immunodeficiency virus from genital ulcers in Nairobi prostitutes. J Infect Dis (1989) 2.41

Detection of HIV DNA in cervical and vaginal secretions. Prevalence and correlates among women in Nairobi, Kenya. JAMA (1993) 2.41

Antibodies to Chlamydia trachomatis, Mycoplasma hominis, and Neisseria gonorrhoeae in sera from patients with acute salpingitis. Br J Vener Dis (1981) 2.36

Rapid progression to disease in African sex workers with human immunodeficiency virus type 1 infection. J Infect Dis (1995) 2.28

CD8(+) lymphocytes respond to different HIV epitopes in seronegative and infected subjects. J Clin Invest (2001) 2.15

Role of the enteric nervous system in the fluid and electrolyte secretion of rotavirus diarrhea. Science (2000) 2.11

Risk factors for postnatal mother-child transmission of HIV-1. AIDS (2000) 2.08

Complex cellular and subcellular regulation of notch expression during embryonic and imaginal development of Drosophila: implications for notch function. J Cell Biol (1991) 2.05

ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. J Clin Invest (1995) 2.04

Use of inactivated or oral poliovirus vaccine in India. Lancet (1991) 2.03

Abdominal aortic aneurysms. West J Med (1984) 2.02

Human immunodeficiency virus infection in long-distance truck drivers in east Africa. Arch Intern Med (1994) 2.01

Deficiency of the stress kinase p38alpha results in embryonic lethality: characterization of the kinase dependence of stress responses of enzyme-deficient embryonic stem cells. J Exp Med (2000) 1.98

Chlamydia trachomatis from individuals in a sexually transmitted disease core group exhibit frequent sequence variation in the major outer membrane protein (omp1) gene. J Clin Invest (1994) 1.97

Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study. Am J Obstet Gynecol (2001) 1.95

Early T-helper cell defects in HIV infection. AIDS (1991) 1.93

Characterization of type 1 and type 2 cytokine production profile in physiologic and pathologic human pregnancy. Clin Exp Immunol (1996) 1.93

Immune activation in africa is environmentally-driven and is associated with upregulation of CCR5. Italian-Ugandan AIDS Project. AIDS (2000) 1.91

Detection of group C rotavirus in infants with extrahepatic biliary atresia. J Infect Dis (1996) 1.91

Differences in national influenza vaccination policies across the European Union, Norway and Iceland 2008-2009. Euro Surveill (2010) 1.90

HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. AIDS (1999) 1.89

99mTechnetium-dimercaptosuccinic acid scan in the diagnosis of acute pyelonephritis in children: relation to clinical and radiological findings. Pediatr Nephrol (1992) 1.89

The epidemiology of Chlamydia trachomatis within a sexually transmitted diseases core group. J Infect Dis (1996) 1.88

Epidemiology of calicivirus infections in Sweden, 1994-1998. J Infect Dis (2000) 1.88

Treatment of cervicitis is associated with decreased cervical shedding of HIV-1. AIDS (2001) 1.88

Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons. J Infect Dis (1999) 1.88

Molecular detection and epidemiology of Sapporo-like viruses. J Clin Microbiol (2000) 1.86

Immune activation in HIV-infected African individuals. Italian-Ugandan AIDS cooperation program. AIDS (1998) 1.86

Late seroconversion in HIV-resistant Nairobi prostitutes despite pre-existing HIV-specific CD8+ responses. J Clin Invest (2001) 1.85

Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol (1993) 1.84

Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease. Ann Neurol (2000) 1.82

Lymphocyte subsets in human immunodeficiency virus type 1-infected and uninfected children in Nairobi. Pediatr Infect Dis J (2001) 1.81

Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet (1998) 1.80

Hawking radiation from ultrashort laser pulse filaments. Phys Rev Lett (2010) 1.80

Mycotic aortic aneurysms. A reappraisal. Arch Surg (1983) 1.79

Influence of HLA supertypes on susceptibility and resistance to human immunodeficiency virus type 1 infection. J Infect Dis (2000) 1.77

Multicentre study of a new enzymatic method of cholesterol determination. J Clin Chem Clin Biochem (1984) 1.77

Common epitope in human immunodeficiency virus (HIV) I-GP41 and HLA class II elicits immunosuppressive autoantibodies capable of contributing to immune dysfunction in HIV I-infected individuals. J Clin Invest (1989) 1.77

Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins. Proc Natl Acad Sci U S A (1992) 1.77

Outbreak of spontaneous staphylococcal arthritis and osteitis in mice. Arthritis Rheum (1990) 1.75

Protective immunity against HIV infection: has nature done the experiment for us? Immunol Today (1996) 1.75

Limb salvage versus amputation. Preliminary results of the Mangled Extremity Severity Score. Clin Orthop Relat Res (1990) 1.73

Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial. AIDS (1997) 1.73

Neutralizing cross-reactive and non-neutralizing monoclonal antibodies to HIV-1 gp120. AIDS (1990) 1.71

Lower-extremity peripheral arterial disease among patients with end-stage renal disease. J Am Soc Nephrol (2001) 1.70

Association between cervical inflammation and cervical shedding of human immunodeficiency virus DNA. J Infect Dis (1994) 1.70

One-Session treatment of specific phobias in youths: a randomized clinical trial. J Consult Clin Psychol (2001) 1.70

Major differences in 1-month survival between hospitals in Sweden among initial survivors of out-of-hospital cardiac arrest. Resuscitation (2006) 1.69

In vitro T cell function, delayed-type hypersensitivity skin testing, and CD4+ T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus. J Infect Dis (1995) 1.69

Scan of human genome reveals no new Loci under ancient balancing selection. Genetics (2006) 1.68

Risk factors for Chlamydia trachomatis pelvic inflammatory disease among sex workers in Nairobi, Kenya. J Infect Dis (1996) 1.67

Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. AIDS (2000) 1.66

Chlamydia trachomatis infection of the Fallopian tubes. Histological findings in two patients. Br J Vener Dis (1979) 1.65

Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer (2003) 1.65

Chlamydial and gonococcal infections in a defined population of women. Scand J Infect Dis Suppl (1982) 1.64

Two new serotypes of enteric adenovirus causing infantile diarrhoea. Dev Biol Stand (1983) 1.63

Genetic diversity and mosaicism at the por locus of Neisseria gonorrhoeae. J Bacteriol (1999) 1.63

Sexually transmitted infections and vaginal douching in a population of female sex workers in Nairobi, Kenya. Sex Transm Infect (2001) 1.63